Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6517847	BAUSCH	Topical gel delivery system	Aug, 2020 (3 years ago)
US10478502	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)
US11839656	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)
US8809307	BAUSCH	Pharmaceutical formulations containing corticosteroids for topical administration	Nov, 2031 (7 years from now)
US11648256	BAUSCH	Topical compositions and methods for treating psoriasis	Jun, 2036 (12 years from now)
US10426787	BAUSCH	Topical compositions and methods for treating psoriasis	Jun, 2036 (12 years from now)
US10251895	BAUSCH	Topical compositions and methods for treating psoriasis	Jun, 2036 (12 years from now)
US11679115	BAUSCH	Topical compositions and methods for treating psoriasis	Jun, 2036 (12 years from now)

Duobrii is owned by Bausch.

Duobrii contains Halobetasol Propionate; Tazarotene.

Duobrii has a total of 8 drug patents out of which 1 drug patent has expired.

Expired drug patents of Duobrii are:

Duobrii was authorised for market use on 25 April, 2019.

Duobrii is available in lotion;topical dosage forms.

Duobrii can be used as topical treatment of plaque psoriasis in adults.

The generics of Duobrii are possible to be released after 06 June, 2036.

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 25, 2022

Market Authorisation Date: 25 April, 2019

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

Duobrii patents expiration